Innovent Biologics
(OTC) IVBXF
Innovent Biologics Financials at a Glance
Market Cap
$19.34B
Revenue (TTM)
$22.35B
Net Income (TTM)
$719.28M
EPS (TTM)
$0.06
P/E Ratio
166.84
Dividend
$0.00
Beta (Volatility)
0.04 (Low)
Dividend
$0.00
Beta (Volatility)
0.04 (Low)
Price
$11.14
Volume
210
Open
$11.14
Price
$11.14
Volume
210
Open
$11.14
Previous Close
$11.14
Daily Range
$11.14 - $11.14
52-Week Range
$5.12 - $15.12
Dividend
$0.00
Beta (Volatility)
0.04 (Low)
Price
$11.14
Volume
210
Open
$11.14
Previous Close
$11.14
Daily Range
$11.14 - $11.14
52-Week Range
$5.12 - $15.12
IVBXF News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Innovent Biologics
Industry
Biotechnology
Sector
Health CareEmployees
7,502
CEO
De Chao Yu, PhD
Website
www.innoventbio.comHeadquarters
Suzhou, 215123, CN
IVBXF Financials
Key Financial Metrics (TTM)
Gross Margin
82%
Operating Margin
11%
Net Income Margin
6%
Return on Equity
5%
Return on Capital
5%
Return on Assets
2%
Earnings Yield
0.60%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$19.34B
Shares Outstanding
1.74B
Volume
210
Short Interest
0.00%
Avg. Volume
1.48K
Financials (TTM)
Gross Profit
$10.99B
Operating Income
$1.97B
EBITDA
$1.97B
Operating Cash Flow
$1.29B
Capital Expenditure
$1.71B
Free Cash Flow
$418.39M
Cash & ST Invst.
$18.24B
Total Debt
$2.82B
Innovent Biologics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$6.97B
+98.9%
Gross Profit
$6.06B
+144.5%
Gross Margin
86.98%
N/A
Market Cap
$19.34B
N/A
Market Cap/Employee
$3.42M
N/A
Employees
5,659
N/A
Net Income
$20.41M
+97.7%
EBITDA
$715.65M
+196.5%
Quarterly Fundamentals
Net Cash
$15.42B
+109.9%
Accounts Receivable
$1.75B
+74.2%
Inventory
$1.30B
+34.5%
Long Term Debt
$2.02B
-16.0%
Short Term Debt
$800.60M
-34.4%
Return on Assets
2.18%
N/A
Return on Invested Capital
5.03%
N/A
Free Cash Flow
$211.19M
+117.3%
Operating Cash Flow
$313.76M
+150.4%